NCT06119490View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 5, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

September 30, 2026

Conditions
Toxic Epidermal Necrolysis
Interventions
DRUG

Abrocitinib

Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks

DRUG

Tofacitinib

Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Tofacitinib tablets 10 mg per day for 2 weeks

Trial Locations (1)

350000

RECRUITING

Department of Dermatology, the First Affiliated Hospital of Fujian Medical University., Fuzhou

All Listed Sponsors
lead

Peng Zhang

OTHER